SCHEMBL2066259

SCHEMBL2066259

Oc1c[nH]c2cccnc12

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSMD14 O00487 1/20 0.48
METAP2 P50579 2/20 0.45
METAP1 P53582 2/20 0.45
MMP2 P08253 2/20 0.45
TSHR P16473 2/20 0.45
CHRM1 P11229 1/20 0.45
COMT P21964 1/20 0.45
ADRA1A P35348 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HSP90AA1 P07900 3/20 0.44
HSP90AB1 P08238 1/20 0.44
IDO1 P14902 1/20 0.44
PSMB5 P28074 1/20 0.44
KCNMA1 Q12791 1/20 0.43
GRM4 Q14833 2/20 0.43
DAO P14920 1/20 0.41
KDM4E B2RXH2 5/20 0.40
LMNA P02545 3/20 0.40
HTT P42858 3/20 0.40
L3MBTL1 Q9Y468 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13978041 0.79 PSMD14 (0.48) PSMD14MMP2TSHRHSP90AA1KCNMA1
SCHEMBL2053968 0.75 PSMD14 (0.48) PSMD14METAP2METAP1MMP2TSHR
SCHEMBL31307015 0.75 PSMD14 (0.48) PSMD14MMP2TSHRHSP90AA1HSP90AB1
SCHEMBL369216 0.75 PSMD14 (0.48) PSMD14MMP2TSHRHSP90AA1GRM4
SCHEMBL19100792 0.75 GRM4 (0.54) PSMD14METAP2METAP1MMP2TSHR
SCHEMBL569155 0.75 AXL (0.50) PSMD14MMP2TSHRHSP90AA1KCNMA1
SCHEMBL3175822 0.75 PSMD14 (0.48) PSMD14MMP2TSHRHSP90AA1HSP90AB1
SCHEMBL29364091 0.75 AXL (0.50) PSMD14MMP2TSHRHSP90AA1KCNMA1
SCHEMBL22510135 0.75 PSMD14 (0.48) PSMD14MMP2TSHRHSP90AA1GRM4
SCHEMBL369215 0.75 PSMD14 (0.48) PSMD14MMP2TSHRHSP90AA1KCNMA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2582709-B1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI SA (FR) 2018-01-24 EP claimed
EP-2001879-B1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE SANOFI SA (FR) 2013-08-21 EP claimed
US-20130157941-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI (FR) 2013-06-20 US claimed
US-8148395-B2 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases SANOFI-AVENTIS (FR) 2012-04-03 US claimed
US-20090054478-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-02-26 US claimed
EP-2001879-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE sanofi-aventis (FR) 2008-12-17 EP claimed
WO-2007110216-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE SANOFI-AVENTIS (DE) 2007-10-04 WO claimed
US-20190292149-A1 ARYL SUBSTITUTED INDOLES AND THE USE THEREOF PURDUE PHARMA LP (US) 2019-09-26 US disclosed
US-10202344-B2 Aryl substituted indoles and the use thereof PURDUE PHARMA L.P. (US) 2019-02-12 US disclosed
US-20180022699-A1 ARYL SUBSTITUTED INDOLES AND THE USE THEREOF PURDUE PHARMA L.P. 2018-01-25 US disclosed
US-8933024-B2 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases SANOFI (FR) 2015-01-13 US disclosed
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 US disclosed
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION CLEAVE BIOSCIENCES, INC. (US) 2014-08-21 US disclosed
EP-2001879-B1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE SANOFI SA (FR) 2013-08-21 EP disclosed
US-20130157941-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI (FR) 2013-06-20 US disclosed
WO-2012158435-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION ZHOU HAN-JIE (US) 2012-11-22 WO disclosed
US-8148395-B2 Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases SANOFI-AVENTIS (FR) 2012-04-03 US disclosed
US-20090054478-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES SANOFI-AVENTIS (FR) 2009-02-26 US disclosed
EP-2001879-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE sanofi-aventis (FR) 2008-12-17 EP disclosed
WO-2007110216-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF ENDOTHELIAL LIPASE SANOFI-AVENTIS (DE) 2007-10-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140235548-A1 COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION USP24, USP36, USP39 PSMD14 7/4885METAP2 3619/4885METAP1 2779/4885
US-20190292149-A1 ARYL SUBSTITUTED INDOLES AND THE USE THEREOF TRPC5, TRPV5, TRPV1 PSMD14 4552/4885METAP2 2506/4885METAP1 1265/4885
US-20090054478-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES PNLIP, LPL, CEL PSMD14 3176/4885METAP2 202/4885METAP1 143/4885
US-20180022699-A1 ARYL SUBSTITUTED INDOLES AND THE USE THEREOF TRPC5, TRPV5, TRPV1 PSMD14 4552/4885METAP2 2506/4885METAP1 1265/4885
US-20130157941-A1 AZOLOPYRIDIN-3-ONE DERIVATIVES AS INHIBITORS OF LIPASES AND PHOSPHOLIPASES PNLIP, LPL, CEL PSMD14 3050/4885METAP2 150/4885METAP1 109/4885
US-10202344-B2 Aryl substituted indoles and the use thereof TRPC5, TRPV5, TRPV1 PSMD14 4552/4885METAP2 2506/4885METAP1 1265/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.